Page results
-
A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.
-
One of our patients who is recovering from COVID-19 has been appearing across national media as she recounts her story and thanks the staff who saved her life.
-
UCLH is managing one of the three cancer hubs across London, so that during the COVID-19 coronavirus pandemic cancer surgery is available for patients with the most immediate needs.
-
Today is International Clinical Trials Day, an important day on the UCLH calendar because research is an integral part of UCLH’s mission.
-
Two UCLH nurses who have dedicated their entire career to the NHS were invited to attend a VE Day celebration concert last Thursday.
-
This page explains what a gastroscopy is and what it involves.
-
This page provides information for patients who are due to be admitted to hospital for bowel surgery.
-
T16 North is a specialist adult haematology inpatient ward dedicated to providing high-quality care for patients with a wide range of blood disorders.
-
Information about making a donation to the Haematology Cancer Care charity fund at UCLH
-
This page provides information about food and drink which may affect your ileostomy output.
File results
-
FOI/2024/0371 - Acute myeloid leukaemia treatment
-
FOI/2024/0365 - Specialist clinical systems to manage patients and patient clinical notes
-
FOI/2024/0363 - Freedom of Information responses available for Mesh requests
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer